Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-11-22
2010-10-12
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S186100
Reexamination Certificate
active
07811581
ABSTRACT:
Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the outer cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.
REFERENCES:
patent: WO 90/04176 (1990-04-01), None
patent: WO 92/00525 (1992-01-01), None
patent: WO 96/20723 (1996-07-01), None
patent: WO 01/37868 (2001-05-01), None
Dukers et al. The Journal of Immunology, 2000, 165:663-670.
Duraiswamy et al. Blood, 2003, 101:3150-3156.
Bharadwaj et al. Expert Rev. Vaccines, 2002, 1(4):467-476.
Miller et al. Oncogene, 1998, 16:1869-1877.
Moss et al. Springer Seminars in Immunopathology, 1991, 13:147-156.
Khanna R. et al; Identification of Cytotoxic T Cell Epitopes within Epstein-Barr Virus (EBV) Oncogene Latent Membrane Protein 1 (LMP1): Evidence Forhla A1 Supertype-Restricted Immune Recognition of EBV-Infected Cells by LMP1-Specific Cytotoxic T. Lymphocytes; Eropean Journal of Immunology, Weinheim. DE, vol. 28, No. 2 Feb. 1998; pp. 451-458.
Strockbine, L et al.; The Epstein-Barr virus BARF1 Gene Encodes a Novel, Soluble Colony-stimulating factor-1 Receptor; Journal of Virology; Mar. 1998, vol. 72. No. 5 pp. 4015-4021; Seattle, WA 98105.
Meij P et al. Restricted Low-Level Human Antibody Responses Against Epstein-Barr Virus (EBV)-Encoded Latent Membrane Protein 1 in a Subgroup of Patients with EBV-Associated Diseases; The Journal of Infectious Diseases; US, May 1999; vol. 179 No. 5, May 1999, pp. 1108-1115.
Leen A. et al.; Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4 (+) T-Helper 1 Responses; Journal of Virology, US, Sep. 2001, vol. 75, No. 18, pp. 8649-8659.
Rowe, David T.; Epstein-Barr Virus Immortalization and Latency; Frontiers In Bioscience, Mar. 15, 1999; vol. 4, No. Cited Mar. 16, 1999; pp. D346-D371; HTTP://www.bioscience.org/ 1999/V4/D/Rowe/FULLTEXT.HTM.
Chen Stacy B
Cyto-Barr B.V.
Hoffmann & Baron , LLP
LandOfFree
Epstein Barr Virus (EBV) tumor-associated latent membrane... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Epstein Barr Virus (EBV) tumor-associated latent membrane..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epstein Barr Virus (EBV) tumor-associated latent membrane... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4154553